Your browser doesn't support javascript.
loading
Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system.
Lopes da Silva Filho, Agnaldo; Luis Pereira Bueno, Ricardo; Ramires, Yohanna; Lino, Lara Marina Cruz.
Afiliação
  • Lopes da Silva Filho A; Medicine Faculty, Gynecology Department, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Luis Pereira Bueno R; Business Graduate Program of University 9 of July (PPGA-UNINOVE), São Paulo, Brazil.
  • Ramires Y; Organon & Co., São Paulo, Brazil.
  • Lino LMC; Organon & Co., São Paulo, Brazil.
PLoS One ; 19(3): e0301207, 2024.
Article em En | MEDLINE | ID: mdl-38547099
ABSTRACT
High rates of unplanned pregnancies persist despite pharmacological developments and advancements in contraceptive methods. Here, we demonstrate that the etonogestrel-releasing subdermal contraceptive implant (IMP-ETN) may be an appropriate and cost-effective alternative to levonorgestrel-releasing intrauterine systems (LNG-IUSs) for women in Brazil. For our pharmacoeconomic analysis, we reviewed the literature on IMP-ETN regarding its acceptance, eligibility criteria, choice, relations with age, adverse events and, finally, the unmet need in the fee-for-service private healthcare sector. We considered qualitative observations in combination with quantitative analysis and performed a deterministic sensitivity analysis to investigate whether this technology can be self-sustainable over a period of five years. The target population for this analysis comprised 158,696 women. Compared with the continued use of LNG-IUSs, adopting the IMP-ETN can result in a cost avoidance of $ 7.640.804,02 in the first year and $ 82,455,254.43 in five years. Disseminating information among physicians will promote this change and strengthen the potential cost avoided by private health system payers. These savings can be used to improve other healthcare programs and strategies. Moreover, the principles of care can be promoted by improving and adapting healthcare systems and expanding treatment and follow-up strategies. This would also provide support to women's reproductive rights and improve their quality of life. Our results suggest that the IMP-ETN has a favorable cost-effectiveness profile. Given all its advantages and negative incremental cost impact over a period of five years, the IMP-ETN may be a more favorable alternative to LNG-IUSs. Therefore, it should be offered to beneficiaries with a private healthcare plan. This analysis overcomes previous barriers to the use of cost-benefit models, and our results may help balance decision-making by policymakers, technical consultants, and researchers.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desogestrel / Anticoncepcionais Femininos / Dispositivos Intrauterinos Medicados Limite: Female / Humans / Pregnancy País/Região como assunto: America do sul / Brasil Idioma: En Revista: PLoS ONE (Online) / PLoS One / PLos ONE Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desogestrel / Anticoncepcionais Femininos / Dispositivos Intrauterinos Medicados Limite: Female / Humans / Pregnancy País/Região como assunto: America do sul / Brasil Idioma: En Revista: PLoS ONE (Online) / PLoS One / PLos ONE Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos